926MO MK-1084 monotherapy in participants (Pts) with KRAS G12C–mutated advanced solid tumors: Activity and safety in the phase I KANDLELIT-001 study.
Saved in:
| Title: | 926MO MK-1084 monotherapy in participants (Pts) with KRAS G12C–mutated advanced solid tumors: Activity and safety in the phase I KANDLELIT-001 study. |
|---|---|
| Authors: | Simonelli, M.1 (AUTHOR), Rojas, C.I.2 (AUTHOR), Dziadziuszko, R.3 (AUTHOR), Park, J.O.4 (AUTHOR), Xue, J.5 (AUTHOR), Felip, E.6 (AUTHOR), Moreno Garcia, V.7 (AUTHOR), Bar, J.8 (AUTHOR), Lakhani, N.9 (AUTHOR), Kwiatkowski, M.10 (AUTHOR), Ahern, E.S.11 (AUTHOR), Lee, J.12 (AUTHOR), Joerger, M.13 (AUTHOR), Stathis, A.14 (AUTHOR), Pal, A.15 (AUTHOR), Dizdar, O.16 (AUTHOR), Jemielita, T.17 (AUTHOR), Choi, S.Y.18 (AUTHOR), Molife, R.L.19 (AUTHOR), Sacher, A.20 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS606-S607. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
